問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Rheumatology

Division of General Internal Medicine

Taipei Chang Gung Medical Foundation

Division of Rheumatology

更新時間：2023-09-19

張哲慈
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

43Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張哲慈

List

64Cases

2024-10-01 - 2027-12-31

Phase II

Active
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    SYSTEMIC LUPUS ERYTHEMATOSUS

  • Test Drug

    injection

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2025-09-16 - 2031-12-31

Phase II

Active
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

  • Condition/Disease

    Radiographic Axial Spondyloarthritis

  • Test Drug

    皮下注射劑

Participate Sites
7Sites

Recruiting7Sites

2018-08-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-08-01 - 2027-05-31

Phase III

Active
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout

  • Condition/Disease

    Gout

  • Test Drug

    AR882

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-07-09 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2027-10-11

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-08-09 - 2026-08-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2019-09-01 - 2024-05-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB